Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

Cardiorenal outcomes with SGLT2 inhibitors in stage 5 chronic kidney disease

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.

Annals of internal medicine

Citation & Authors

Ann Intern Med. 2024;177(6):693-700.

Fu-Shun Yen; Chii-Min Hwu; Jia-Sin Liu; Yi-Ling Wu; Keong Chong; Chih-Cheng Hsu

ABSTRACT · RESEARCH SUMMARY

Research summary

This Taiwanese National Health Insurance target trial emulation compared approximately 24,000 users with approximately 24,000 nonusers, all with type 2 diabetes and stage 5 chronic kidney disease. SGLT2 inhibitors were associated with lower risks of dialysis (HR 0.34; 95% CI 0.27–0.43), heart failure hospitalization, and myocardial infarction. All-cause mortality did not differ significantly (1.11; 0.99–1.24). These findings cannot be directly extrapolated to patients without diabetes.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗